The U.S. Food and Drug Administration (FDA) has cleared GE HealthCare's Allia IGS Pulse image-guided system for the diagnosis and treatment of cardiovascular diseases in interventional cardiology.
The system features a monopolar x-ray tube, which GEHC says translates to high image quality and optimized dose management regardless of patient size. It also includes the firm's MyIQ technology, which allows users to choose their favorite image from a library of four styles, and AutoRight Plus, the next generation of the company's automation platform, AutoRight.
GEHC plans to showcase Allia IGS Pulse at the upcoming Transcatheter Cardiovascular Therapeutics 2023 conference in San Francisco.
